Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies : The GETH/GELTAMO Experience
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Bento, Leyre (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Novelli, Silvana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Martin, Alejandro (Hospital Universitario de Salamanca)
Gutierrez, Gonzalo (Hospital Clínic i Provincial de Barcelona)
Salas, Maria Queralt (Hospital Clínic i Provincial de Barcelona)
Bastos, Mariana (Hospital General Universitario Gregorio Marañón)
Perez, Ariadna (Hospital Clínic Universitari (València))
Hernani, Rafael (Hospital Clínic Universitari (València))
Viguria, Maria Cruz (Complejo Hospitalario de Navarra)
Lopez-Godino, Oriana (Hospital General Universitario Morales Meseguer (Múrcia))
Montoro, Juan (Hospital Universitari i Politècnic La Fe (València))
Piñana, José Luis (Hospital Universitari i Politècnic La Fe (València))
Ferrá, Christelle (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Parody Porras, Rocío (Institut Català d'Oncologia)
Martin, Carmen (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Español, Ignacio (Hospital Universitario Virgen de la Arrixaca (Múrcia))
Yañez, Lucrecia (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria))
Rodriguez, Guillermo (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Zanabili, Joud (Hospital Asturias)
Herrera, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
Varela, Maria Rosario (Complejo Hospital Juan Canalejo)
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Solano, Carlos (Hospital Clínic Universitari (València))
Caballero, Dolores (Hospital Universitario de Salamanca)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2022
Abstract:	Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Cancers, Vol. 14 Núm. 11 (6-1 2022) , p. 2673, ISSN 2072-6694

DOI: 10.3390/cancers14112673
PMID: 35681653

16 p, 1.7 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles